Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CTC detection in early stage lung adenocarcinoma
NCT02951897Unknown
- Sponsor
- Army Medical University
- Start
- Apr 2016
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of pemetrexed and cisplatin in lung adenocarcinoma (6 arms), sponsored by Army Medical University. Primary endpoint: Disease free survival at 60 months. Status: unknown.
02
Drugs
pemetrexedcisplatin
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT02951897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02951897.